The latest news: Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared to temozolomide-chemoradiation for unresectable glioblastoma. Final results of the TEMAVIR study from ANOCEF. This trial did not show much benefit for using Avastin and Irinotecan for newly diagnosed unresectable GBMs. There was no difference in overall survival, however, the patients in the control group were able to cross over when the progressed, and there was about a 2 month advantage in time to progression. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. This is a small trial of the ketogenic diet with and without Avastin, and it didn't help at all, however, this is not the same low calorie ketogenic diet that has shown some promise. Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna. This is a perfect example of how you can use statistics incorrectly to make anything look good. The inclusion group was defined as patients who had at least 3 homeopathic consults in 4 years. If you take any group of cancer patients and only count those that lived 4 years, of course they are going to show better results. This doesn't capture those for whom the treatment did not work. New Clinical Trials Finder on Virtualtrials.com I am proud of this new feature on the website and would like to thank Stephen Western for his help with the project. Let me know how you like it and if there is anything we can add to make it better! BrainTumor Co-Payment Assistance Program Status: CLOSED to new applicants
